Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
4.71 EUR | -0.21% | -0.63% | +1.51% |
14/03 | GHC, revenues up but profit falls after Aurelia acquisition | AN |
14/03 | Garofalo Health Care S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.51% | 446M | B | ||
-18.46% | 16.57B | B+ | ||
+4.50% | 12.4B | B | ||
+4.98% | 11.69B | B+ | ||
+4.26% | 10.24B | B+ | ||
+24.97% | 8.35B | B | ||
-2.91% | 7.76B | A- | ||
+20.21% | 7.17B | D | ||
+5.48% | 6.74B | B- | ||
+50.68% | 4.65B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GHC Stock
- Ratings Garofalo Health Care S.p.A.